Xiamen Kingdomway Group Company (002626.SZ) has announced that its wholly-owned subsidiary, Inner Mongolia Kingdomway Pharmaceutical Co., Ltd. ("Kingdomway Pharmaceutical"), recently received a no objection response letter for GRAS Notice No. GRN 001305 issued by the U.S. Food and Drug Administration (FDA).

The Brazzein preparation product of Kingdomway Pharmaceutical has completed the FDA GRAS notification evaluation, and the FDA issued a no objection opinion regarding the GRAS (Generally Recognized as Safe) conclusion for the product under its declared use.

Brazzein preparation is a protein-based high-intensity sweetener with sweetness approximately 500 to 2,000 times that of sucrose. It can be used as a general-purpose sweetener in the food sector and demonstrates excellent compatibility in blending applications.

Brazzein does not participate in the human sugar metabolism pathway, does not raise blood glucose levels, and is broken down into amino acids after entering the human body, providing almost no calories. It caters to the needs of sugar-conscious consumers and those managing weight, and holds broad market application prospects.

The receipt of the FDA GRAS no objection letter for Kingdomway Pharmaceutical's Brazzein product signifies that the safety conclusion of the product has passed the FDA's official review without objection. The product now possesses an important compliance foundation for entering the U.S. food market, which is conducive to the company's efforts to expand its related products into overseas markets, enrich its food ingredient product matrix and revenue streams, and enhance its comprehensive competitiveness in the synthetic biology field. It is expected to have a positive impact on the company's future development.